BMC cancer · 2026
Upregulation of miR-32 in tissue and plasma and its association with PTEN expression in colorectal cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mehrjoei Bayan, Tahmasebi Susan, Haghnazari Lida, Rezvani Parmida, Bashiri Homayoon, Rezvani Nayebali
Аннотация
BACKGROUND: Early detection of colorectal cancer (CRC) is critical for improving patient outcomes. MicroRNAs (miRNAs) function as post-transcriptional regulators and have emerged as potential minimally invasive diagnostic biomarkers. Although miR-32 has been implicated in tumor progression in several malignancies, its expression pattern in CRC tissue and plasma and its association with PTEN expression require further clarification.
MATERIALS AND METHODS: Expression levels of miR-32 and PTEN were measured using quantitative real-time PCR (qRT-PCR) in tumor tissues, adjacent normal tissues, and plasma samples from 55 CRC patients and plasma samples from 55 age and sex matched healthy controls.
RESULTS: MiR-32 expression was significantly upregulated in CRC tissues and plasma samples, whereas PTEN expression was significantly reduced in tumor tissues (P < 0.001). ROC curve analysis demonstrated strong diagnostic performance of miR-32 in tissue (AUC = 0.942) and good performance in plasma (AUC = 0.846). An inverse association between miR-32 and PTEN expression was observed. Higher miR-32 levels were also associated with advanced tumor stage.
CONCLUSIONS: This is the first report of concurrent miR-32 upregulation and PTEN downregulation in both CRC tissue and plasma. MiR-32 may represent a potential non-invasive biomarker candidate for CRC detection and disease stratification. However, these findings are observational and require validation in larger, multicenter cohorts and functional studies before clinical application.
MATERIALS AND METHODS: Expression levels of miR-32 and PTEN were measured using quantitative real-time PCR (qRT-PCR) in tumor tissues, adjacent normal tissues, and plasma samples from 55 CRC patients and plasma samples from 55 age and sex matched healthy controls.
RESULTS: MiR-32 expression was significantly upregulated in CRC tissues and plasma samples, whereas PTEN expression was significantly reduced in tumor tissues (P < 0.001). ROC curve analysis demonstrated strong diagnostic performance of miR-32 in tissue (AUC = 0.942) and good performance in plasma (AUC = 0.846). An inverse association between miR-32 and PTEN expression was observed. Higher miR-32 levels were also associated with advanced tumor stage.
CONCLUSIONS: This is the first report of concurrent miR-32 upregulation and PTEN downregulation in both CRC tissue and plasma. MiR-32 may represent a potential non-invasive biomarker candidate for CRC detection and disease stratification. However, these findings are observational and require validation in larger, multicenter cohorts and functional studies before clinical application.